Cargando…
Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions
Pancreatic cancer (PDAC) is an aggressive and chemoresistant disease, representing the fourth cause of cancer related deaths in western countries. Majority of patients have unresectable, locally advanced or metastatic disease at time of diagnosis and the 5-year survival rate in these conditions is e...
Autores principales: | Giordano, Guido, Pancione, Massimo, Olivieri, Nunzio, Parcesepe, Pietro, Velocci, Marianna, Di Raimo, Tania, Coppola, Luigi, Toffoli, Giuseppe, D’Andrea, Mario Rosario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583572/ https://www.ncbi.nlm.nih.gov/pubmed/28932079 http://dx.doi.org/10.3748/wjg.v23.i32.5875 |
Ejemplares similares
-
Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept
por: Giordano, Guido, et al.
Publicado: (2014) -
Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches
por: Parente, Paola, et al.
Publicado: (2018) -
Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer
por: Parcesepe, Pietro, et al.
Publicado: (2016) -
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer
por: Giordano, Guido, et al.
Publicado: (2019) -
Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era
por: Giordano, Guido, et al.
Publicado: (2021)